SEOUL, KOREA - The sales revenue of Dong-A Pharmaceuticals has grown 6.9 percent last year on the back of the favorable sales performance of its flagship energy drink "Bacchus." According to an announcement by Dong-A Socio Holdings on February 10, its drug unit's financial results for 2013 were mostly led by an increase in non-prescription drug sales.

 

 

For the ten-month period between March and December last year since the spin-off of Dong-A ST on March 1, the sales revenue of Dong-A Pharmaceuticals has been 289.7 billion won, with the operating profit of 37.8 billion won (operating profit ratio of 13%).

 

The sales revenue for the whole year of 2013 estimated by the company was 331.4 billion won, up 6.9 percent from the previous year's 310.0 billion won. The operating profit estimated for the whole year was 42.1 billion won (operating profit ratio of 12.7%).

 

Of the sales revenue, that for Bacchus accounted for more than 50 percent. The Bacchus sales alone logged in 179.2 billion won, up 4.9 percent from the previous year. The sales of "Gagrin," an antiseptic mouthwash brand, rose 4.2 percent to 22.3 billion won.